St. Jude pacing
This article was originally published in The Gray Sheet
Executive Summary
New comorbidity indications, including syncopy and sleep apnea, are among the enhancements St. Jude hopes to add to its line of AF-suppressing, low-voltage bradycardia systems, the company tells investors during its Q1 earnings call April 17. The development is one of several initiatives to be discussed at the firm's May 1-2 analyst meeting in Minnesota. St. Jude also will discuss the launch of a porcine stented tissue valve in 2003 and may also provide further detail on the VecTor trial of the EPIC HF high-voltage resynchronization system, which is expected to gain PMA approval in 2003...